> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bipartisan Patent Coordination Bill In
- URL: https://www.fdaweb.com/bipartisan-patent-coordination-bill-in/
- Published: 2025-03-27T12:00:00.000Z
- Updated: 2026-09-14T14:56:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158903

Sens. **Charles Grassley** (R-IA), **Richard Durbin** (D-IL), **Thom Tillis** (R-NC), **Peter Welch** (D-VT), and **Chris Coons** (D-DE) have introduced the Interagency Patent Coordination and Improvement Act to establish a task force between FDA and the U.S. Patent and Trademark Office to “improve communication and coordination in implementing each agency’s activities related to pharmaceutical patents.” A [statement](https://www.judiciary.senate.gov/press/rep/releases/grassley-durbin-colleagues-introduce-legislation-to-improve-coordination-between-patent-office-and-fda?ref=fdaweb.com) from the Senate Judiciary Committee, which Grassley chairs and on which all the bill’s sponsors serve, says the task force would:

- enhance information sharing on each agency’s processes, standards, and methods;
- improve dialog on new technologies and scientific trends;
- enable confidential reciprocal access to information, if requested and only as needed, related to prior art;
- ensure accurate representations by companies between the two agencies; and
- ensure the accuracy of patent listings.

“The bill promotes efficiency and good governance,” the statement says, “by fostering communication between the two agencies, while respecting their distinct purviews. This enhanced coordination will help bolster innovation while preventing inappropriate tactics to delay access to affordable generic medications.”